A protocol for a multicentre randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients with severe sepsis: the BLING II study.

J Dulhunty, J Roberts, Joshua Davis, S Webb, R Bellomo, C Gomersall, C Shirwadkar, G Eastwood, J Myburgh, David Paterson, T Starr, A Udy, S Paul, J Lipman

    Research output: Contribution to journalArticle

    20 Citations (Scopus)

    Abstract

    Background and rationale: Beta-lactam antibiotics are largely administered by bolus dosing, despite displaying time-dependent pharmacokinetics and pharmacodynamics and there being a strong rationale for continuous administration. The randomised controlled trials conducted to date comparing the mode of beta-lactam administration have been inconclusive and limited by non-equivalent dosing, unblinded administration and small sample sizes. Objective: A multicentre, randomised controlled trial (the Beta-lactam Infusion Group [BLING] II study) is currently under way, comparing continuous infusion to standard bolus administration of beta-lactam antibiotics in critically ill patients, independent of dose. Design, settings, participants and interventions: BLING II is a Phase IIB, double-blinded, randomised controlled trial recruiting 420 intensive care unit patients with severe sepsis to receive one of three beta-lactam study antibiotics (ticarcillin-clavulanate, piperacillin-tazobactam or meropenem) by either continuous infusion or intermittent bolus administration. Main outcome measures: The primary outcome is ICU-free days at Day 28. Secondary outcomes include 90-day survival, clinical cure 14 days after study antibiotic cessation, organ failure-free days at Day 14 and duration of bacteraemia. Results and conclusions: The study started in July 2012 and will provide clinical evidence as to whether continuous infusion of beta-lactam antibiotics is superior to intermittent bolus administration in critically ill patients with severe sepsis. A Phase III study powered for a survival end point may be justified, based on the results of our study.

    Original languageEnglish
    Pages (from-to)179-185
    Number of pages7
    JournalCritical Care and Resuscitation
    Volume15
    Issue number3
    Publication statusPublished - 2013

    Fingerprint Dive into the research topics of 'A protocol for a multicentre randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients with severe sepsis: the BLING II study.'. Together they form a unique fingerprint.

  • Cite this

    Dulhunty, J., Roberts, J., Davis, J., Webb, S., Bellomo, R., Gomersall, C., Shirwadkar, C., Eastwood, G., Myburgh, J., Paterson, D., Starr, T., Udy, A., Paul, S., & Lipman, J. (2013). A protocol for a multicentre randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients with severe sepsis: the BLING II study. Critical Care and Resuscitation, 15(3), 179-185.